 Point mutations in adenylosuccinate that cause lowered enzymatic activity cause clinical symptoms that mark the condition adenylosuccinate lyase deficiency.This protein may use the morpheein model of allosteric regulation.Adenylosuccinate lyase (ASL) is an enzyme that catalyzes two reactions in the "de novo" purine biosynthetic pathway.